Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_2

40%

Ph early_phase_1

20%

Ph not_applicable

20%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Other(1)

Detailed Status

Terminated2

Suspended1

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 22 (40.0%)

N/A1 (20.0%)

Trials by Status

terminated240%

suspended120%

completed120%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

NCT05081882

suspendedearly_phase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT05081882Phase 2

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

Terminated

NCT06213298Early Phase 1

Effect of Kava on Anxiety and Stress in Cancer Survivors

Suspended

NCT03606655Phase 1

Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK

Withdrawn

NCT02500472Not Applicable

Investigation of Kava Effects on NNK Metabolism

Completed

NCT00083980Phase 2

Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5